Skip to content

Study · Non-randomized trial · n = 6 · 1995

3 results

Modulation of growth hormone-releasing activity of hexarelin in man.

Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E

Neuroendocrinology1 Jan 1995Cited by 37 (Europe PMC)

PMID7731498 (opens in a new tab)DOI10.1159/000126827 (opens in a new tab)PepBankPUB-07731498
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, hexarelin induced a higher GH increase than GHRH.

    In plain wordsIn healthy men, hexarelin raised GH more than GHRH did.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release (AUC0-120) after hexarelin versus GHRH
    Study

    n = 6

    Comparator
    GHRH 2 micrograms/kg iv
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    GH AUC0-120
    4.693 micrograms.min/l
    hexarelin
    GH AUC0-120
    1.494 micrograms.min/l
    GHRH

    Source sentences

    Summary
    Hexarelin induced a higher increase in GH levels as compared to GHRH (integrated output calculated as area under the curve AUC0-120 4,693 +/- 691 vs. 1,494 +/- 102 micrograms.min/l, p < 0.01).
    1 context sentence
    Summary · context
    In a first experiment conducted on 6 healthy male volunteers, we studied the interaction of the maximally effective intravenous dose of hexarelin (2 micrograms/kg i.v.) with GH-releasing hormone (GHRH, 2 micrograms/kg i.v.) and somatostatin (2 micrograms/kg/h i.v.).

Studies that did not test the peptide alone2

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 02HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome

    In healthy men, coadministration of hexarelin and GHRH produced a higher GH response than hexarelin alone.

    In plain wordsIn healthy men, hexarelin together with GHRH raised GH more than hexarelin alone.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH response to hexarelin plus GHRH versus hexarelin alone
    Study

    n = 6

    Comparator
    Hexarelin alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC0-120
    7.395 micrograms.min/l
    hexarelin plus GHRH

    Source sentences

    Summary
    Coadministration of hexarelin and GHRH produced a higher GH response than hexarelin alone (AUC0-120 7,395 +/- 450 micrograms.min/l, p < 0.05).
    1 context sentence
    Summary · context
    In a first experiment conducted on 6 healthy male volunteers, we studied the interaction of the maximally effective intravenous dose of hexarelin (2 micrograms/kg i.v.) with GH-releasing hormone (GHRH, 2 micrograms/kg i.v.) and somatostatin (2 micrograms/kg/h i.v.).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 03HumanNot a test of Hexarelin aloneNon-randomized trialEfficacy outcome

    In healthy men, somatostatin infusion blunted but did not abolish the GH response to hexarelin.

    In plain wordsIn healthy men, somatostatin reduced the GH rise caused by hexarelin but did not stop it.

    Peptide
    Hexarelin
    Outcome
    DecreaseEffect of somatostatin on the GH response to hexarelin
    Study

    n = 6

    Comparator
    Hexarelin without somatostatin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC0-120
    1.314 micrograms.min/l
    hexarelin with somatostatin

    Source sentences

    Summary
    Somatostatin abolished the GH response to GHRH (AUC0-120 363 +/- 89 micrograms.min/l, p < 0.01), while it only blunted that to hexarelin (AUC0-120 1,314 +/- 297 micrograms.min/l, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
    1 context sentence
    Summary · context
    In a first experiment conducted on 6 healthy male volunteers, we studied the interaction of the maximally effective intravenous dose of hexarelin (2 micrograms/kg i.v.) with GH-releasing hormone (GHRH, 2 micrograms/kg i.v.) and somatostatin (2 micrograms/kg/h i.v.).

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.